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Tramadol is a well-known and effective analgesic. Recently it was shown that tramadol is also 
effective in human premature ejaculation. The inhibitory effect of tramadol on the ejaculation 
latency is probably due to its mechanism of action as a µ-opioid receptor agonist and noradrena-
line/serotonin (5-HT) reuptake inhibitor. In order to test this speculation, we tested several doses 
of tramadol in a rat model of male sexual behavior and investigated two types of drugs interfering 
with the µ-opioid and the 5-HT system. First the µ-opioid receptor agonist properties of tramadol 
were tested with naloxone, a µ-opioid receptor antagonist. Second, the effects of WAY100,635, a 
5-HT1A receptor antagonist, were tested on the behavioral effects of tramadol. Finally the effects 
of paroxetine, a selective serotonin reuptake inhibtor, combined with naloxone or WAY100,635 
treatment, were compared to the effects of tramadol combined with these drugs.  
Results showed that naloxone, at a sexually inactive dose, could only partially antagonize the 
inhibitory effect of tramadol. Moreover, low and behaviorally inactive doses of WAY100,635, 
strongly decreased sexual behavior when combined with a behaviorally inactive dose of tra-
madol. Finally we showed that the effects of paroxetine on sexual behavior resembled the effects 
of tramadol, indicating that tramadol’s inhibitory effects on sexual behavior are primarily and 
mainly caused by its SSRI properties and that its µ-opioid receptor agonistic activity only con-
tributes marginally. These findings support the hypothesis that tramadol exerts inhibition of 
premature ejaculations in men by its 5-HT reuptake inhibiting properties. 
 


















Tramadol is a centrally acting and clinically approved and used drug for pain treatment (Shipton 
2000). Tramadol is a weak µ-opioid receptor agonist, probably acting via its active metabolite O-
desmethyltramadol (M1), which has a 10-fold lower affinity for the µ-opioid receptor than mor-
phine (Frink et al. 1996; Minami et al. 2015). Tramadol is a racemic mixture of two active enan-
tiomers (Frink et al. 1996). The (+)-enantiomer and its metabolite ((+)-M1) are selective agonists 
of the µ-opioid receptor and have also serotonergic reuptake inhibitory effects (SSRI); the (-)-
enantiomer and the (-)-M1 metabolite are norepinephrine reuptake inhibitors (Matthiesen et al. 
1998). This activity profile suggests antidepressant potency and in animal paradigms, tramadol 
indeed shows antidepressant activity (Rojas-Corrales et al. 1998; 2002). Recently, tramadol has 
been shown, as an off-label application, to be effectiv  in premature ejaculation in humans (Eassa 
and El-Shazly 2013; Yang et al. 2013), comparable to the SSRIs (Waldinger et al. 1998; 2001b; 
2001a; Waldinger and Olivier 2004).  
The present study was undertaken to investigate the pot ntial ‘inhibitory’ effect of tramadol on 
sexual behavior in male rats in analogy to such effects in SSRIs (Bijlsma et al. 2014; Chan et al. 
2008). SSRIs have strong inhibitory effects on sexual behavior both in humans (Waldinger et al. 
1998; 2001b; 2001a) and rodents (Olivier 2011). These ffects are particularly emerging after 
(sub-) chronic dosing and most SSRIs do not exert strong inhibitory effects on sexual behavior 
after acute administration in man (Waldinger and Olivier 2004) or rats (Mos et al. 1999; Olivier 
2011; Waldinger and Olivier 2004), although acutely sometimes inhibitory effects are reported 
(Bijlsma et al. 2014; Olivier 2011). Noradrenergic reuptake inhibiting effects are generally not 
considered to strongly contribute to the inhibitory action on sexual behavior as shown with ven-
lafaxine and other SNRIs (Bijlsma et al. 2014; Segraves and Balon 2014). However, the µ-opioid 















an acute sexual inhibitory effect of tramadol as µ-opiate receptor agonists like morphine exert 
acute inhibitory effects on male sexual behavior in rats (McIntosh et al. 1980; Ågmo and Paredes 
1988). In the present studies, we first explored several doses of tramadol (10, 12.5, 20, 25, 40 and 
50 mg/kg IP, experiments 1 and 6) on sexual behavior of male rats selected and trained for aver-
age sexual activity (2-3 ejaculations per 30-min test at the end of the training). Because only the 
highest dose of tramadol (50 mg/kg) reduced sexual behavior we tried to antagonize these inhibi-
tory effects with naloxone, an opiate receptor antagonist (experiments 2, 3 and 4). In another set 
of studies, we selected a non-sexual behavior inhibiting dose of tramadol (25 mg/kg) and com-
bined it with a selected, sexual behavior-inactive dose of the 5-HT1A receptor antagonist 
WAY100,635 (experiment 5). The idea behind this experiment was based on our previous finding 
that combining sexually inactive doses of a 5-HT1A receptor antagonist with a sexually inactive 
dose of an SSRI after acute administration strongly inhibits sexual behavior (de Jong et al. 2005; 
Olivier 2015). As comparison, we also performed an acute combination study of the SSRI parox-

















2. Materials and Methods 
2.1 Animals 
One hundred and twenty male Wistar rats (Harlan, Zeist, The Netherlands) ranging from 450-500 
g were trained for sexual behavior with a sexually primed intact female rat (50 µg estradiol ben-
zoate in sesame oil saturated with lecithin given 36 hours before testing) once a week for 4 weeks 
in 30-min tests. Training and sex test were performed under red light and reversed light-dark 
conditions (12hLight-12hDark: lights off from 6:00 AM to 6:00 PM) in sex test chambers 
(60cmx 40cmx30cm; rectangular plastic boxes with clear front window and regular bedding ma-
terial).  Bedding of the sex test chambers was not changed during training and testing, to stimu-
late the sexual behavior due to the pheromones. All tests were performed between 9 AM and 4 
PM. After 4 training tests (30 min/training), the male rats were considered sexually trained and 
classified into average ejaculating (2-3 ejaculations(E)/test), fast ejaculating (>3 E/test), and slow 
ejaculating (0-1 E/test) groups based on the ejaculations numbers per test (Chan et al. 2008; 
Olivier et al. 2006; Pattij et al. 2005). A total of 48 rats with an average number of ejaculations 
have been selected and used during all subsequent experiments. In all individual experiments at 
least N=8 rats per dose of a drug were used and rats were maximally used once a week to guaran-
tee sufficient washout of drugs. Rats had ad libitum access to food and water. All experiments 
were conducted in accordance with the governmental guidelines for care and use of laboratory 
animals and was approved by the Ethical Committee for Animal research of the Faculties of Vet-
erinary Medicine, Pharmaceutical Sciences, Chemistry and Biology at Utrecht University. All 


















2.2 Drug treatment and behavioral experiments 
Care was taken that animals did not receive the same drugs or vehicle during all these experi-
ments, which were run over a couple of months. For the pharmacological tests, male rats were 
given a 30-min habituation time in the test chambers.  All drugs were injected IP 30 minutes be-
fore introduction of the female rat. Double injections were given immediately after each other.  
All tests were performed between 9:00 AM-16:00 PM. Behavioral observations over 30-minutes 
after introduction of the female were analyzed using Noldus Observer® (Noldus Information 
Technology, Wageningen, the Netherlands).  The number of ejaculations/test (E) were scored 
and from these data the following parameters of the first ejaculation series were deduced (Chan 
et al. 2011): latency (s) to first mount (ML), latency (s) to first intromission (IL), number of 
mounts (M), number of intromissions (I), and latency (s) to the first ejaculation (EL). After ejacu-
lation, the post ejaculatory latency (PEL) was calcul ted, using the time from the first ejaculation 
and the time of the first mount/intromission (whichever occurred first) of the second ejaculation 
series. Intromission ratio (IR) was calculated as: IR = (#I/(#I + #M)) * 100%.  In the present 
study the main results are deduced from the effects of the treatment (vehicle or dose of a drug) on 
the first ejaculation series, which includes the first post-ejaculatory latency. In order to study 
drugs, it is important to have comparable pharmacodynamics and kinetics, and thus a fixed test 
duration of 30 minutes (1800 sec) is chosen. Because some treatments cause low sexual activities 
(e.g. zero ejaculations) some animals actually cannot be used for statistics. Artificial maximum 
values of 1800 sec (i.e. the test duration) for some latencies (ejaculation latency, mount and in-
tromission latency, post-ejaculatory latency) are us d, although this is certainly a matter of dis-
pute. The mount and intromission data from these non-ejaculating animals are also problematic 
because it is actually unknown whether a rat may eventually ejaculate. These data may be con-















drug inhibited ejaculatory behavior, few or no animal achieve a second ejaculation making statis-
tical analyses of the second ejaculatory series impossible, If in our experiments a drug blocked 
ejaculation in the majority of animals data values of 1800 sec were imputed for EL, ML, IL and 
PEL and also include the frequency values (MF, IF) for all animals for statistical purposes. In 
such cases, the strong inhibitory drug effects warrant the use of these values. We chose to skip 
statistical analyses if less than 50% of animals in a certain drug-treated group were left for second 
ES parameters. All tables only show the results for the first Ejaculation Series. Specifics for a 
certain experiment are described in the legends of the respective tables.  
 
 
2.3 Statistical analyses 
The data was separated into ejaculations series. One-way ANOVA and Bonferroni post-hoc sta-
tistical analysis was used to analyze the data. All data were analyzed using SPSS 16.0 software 
(LEAD technologies, Chicago, USA). Level of significance was set at p < 0.05. Data are ex-
pressed as mean ± SEM.  
 
2.4 Drugs 
Tramadol hydrochloride (obtained from DMI, UK), naloxone hydrochloride and WAY100635 
maleate were bought from Sigma-Aldrich. Paroxetine hydrochloride was prepared from tablets 
obtained from a local pharmacy, grinded and suspended in saline. We have extensive evidence 
that the paroxetine used in this way has an excellent bioavailability that is comparable to that of 
the hydrochloride salt of paroxetine alone (Bijlsma et al. 2014; Chan et al. 2008). All drugs were 
dissolved in 0.9% NaCl (saline), and each solution was freshly prepared for each testing day. All 
















2.5 Pharmacological studies: 
The following studies have been performed: 
Study 1: 48 selected average ejaculating male rats were randomly divided into 4 groups of N=12 
each. Groups received vehicle (saline), 10, 20 or 40 mg/kg tramadol (tramadol hydrochloride). 
Because we physically could not test 48 animals in one test-day, we performed testing over two 
consecutive days and animals and treatment were randomized over these two days. In the next 
experiments (studies 2-6) a lower number of animals w  used. They were randomly chosen from 
the 48 rats available with the restriction that animals never got the same treatment more than once 
and all 48 animals underwent approx. the same number of experimental tests. 
Study 2: 24 animals were treated with vehicle + saline (N=8), vehicle + tramadol (50 mg/kg: 
N=8) and a group with naloxone (10 mg/kg + tramadol 50 mg/kg; N=8). Testing was performed 
on one testing day 
Study 3: 32 rats were either treated with vehicle + vehicle (N=8), vehicle + 5 mg/kg Naloxone 
(N=8), vehicle + naloxone (10 mg/kg; N=8) and vehicle + paroxetine (10 mg/kg; N=8). Testing 
was performed on one testing day 
Study 4: 24 rats were either treated with vehicle (vehicle + vehicle; N=8), vehicle + naloxone (20 
mg/kg; N=8), or tramadol (50 mg/kg) + naloxone (20 mg/kg; N=8). Testing was performed on 
one testing day 
Study 5: 24 rats were either treated with vehicle + vehicle (N=8), WAY100,635 (1 mg/kg) + ve-
hicle (N=8) or WAY 100635 (1 mg/kg) + tramadol (25 mg/kg; N=8). Testing was performed on 
one testing day 
Study 6: 24 rats were either treated with vehicle (N=8), tramadol (12.5 mg/kg; N=8) or tramadol 















Study 7: all 48 rats were either treated with vehicle + vehicle (N=8), vehicle + WAY100635 (0.1 
mg/kg; N=8), vehicle + WAY100635 (0.3 mg/kg; N=8), vehicle + paroxetine (10 mg/kg; N=8), 
WAY 100635 (0.1 mg/kg) + paroxetine (10 mg/kg; N=8) or WAY100635 (0.3 mg/kg) + paroxe-



















3.1 Dose-response study of tramadol 
In the first dose-response study (0, 10, 20, and 40 mg/kg) tramadol had no significant effects on 
any aspects of male sexual behavior (Fig. 1/Suppl. tab e 1). Although there were tendencies that 
the 40 mg/kg dose had some lowering effects on various aspects of the sexual behavior, none of 
the parameters differed significantly from vehicle. Therefore, we decided to use a higher dose of 
tramadol in the next experiment. This 50-mg/kg tramadol dose vs. vehicle experiment (Fig 2/ 
Suppl. table 2), tramadol dramatically reduced sexual behavior. Most animals refrained from any 
sexual activity, most clearly seen by the absence of any ejaculation, long latencies before the first 
mount and intromission in a limited number of animals.  
 
3.2 Antagonism of tramadol’s sexual effects by naloxone. 
Naloxone (5 and 10 mg/kg: Suppl. table 3) had no significant effects on sexual behavior. The 10-
mg/kg dose of naloxone had a very limited partial antagonizing effect on the inhibitory effects of 
50-mg/kg tramadol (Fig 2, suppl. table 2). The latency to the first mount (M1) and first intromis-
sion (I1) were significantly shorter after adding naloxone to tramadol than after tramadol alone. 
Also the total number of mounts (M) and intromission  (I) were significantly enhanced. 
An attempt to further antagonize tramadol’s inhibitory effect by increasing the naloxone dose to 
20 mg/kg failed, because that dose of naloxone itself strongly inhibited sexual behavior (Fig.3, 

















3.2 Combination of tramadol and paroxetine with the 5-HT1A receptor antagonist WAY100,635. 
Paroxetine (10 mg/kg IP) alone has no consistent inhibitory effect on sexual behavior when given 
acutely (suppl. table 3 (last column) and suppl. table 7). But, when this dose was combined with, 
by themselves inactive doses of the 5-HT1A receptor antagonist WAY100,635. (1.0 mg/kg (Fig. 
4, suppl. table 5); 0.1 and 0.3 mg/kg (Fig. 5; suppl. table 7)) sexual behavior was strongly inhibit-
ed (Fig. 4 and Fig. 5 and Suppl. tables 5 and 7). 
When 1.0-mg/kg WAY100,635, that alone has no effect on sexual behavior (Fig.4 and Suppl. 
table 5), was combined with a dose of tramadol (25 mg/kg) that on itself had no significant effect 

















Acutely administered, tramadol has, up to 40-mg/kg (IP) no significant effects on sexual behavior 
of ‘normally’ ejaculating male rats, although some inhibitory trends were seen at the 40-mg/kg 
dose. At 50-mg/kg IP, however, tramadol strongly inhibited sexual behavior, reducing it almost 
to zero. Because tramadol, via its enantiomers and active metabolites, exerts opiate receptor ago-
nistic and 5-HT reuptake inhibiting effects, it was tried to unravel whether tramadol’s effects on 
sexual behavior were related to either of these mechanisms. Naloxone, a µ-opiate receptor antag-
onist had at low doses (5 and 10 mg/kg) no intrinsic effects on sexual behavior. At 20-mg/kg, 
however, naloxone strongly inhibited sexual behavior itself making this dose unfit to try to an-
tagonize tramadol’s inhibitory effects. Naloxone (10 mg/kg) had some minor, but significant, 
antagonizing effects on the inhibitory effects of 50-mg/kg tramadol, suggesting that the µ-opioid 
receptor may play a minor role in this effect. Morphine, a µ-opiate receptor agonist inhibits male 
sexual behavior in rats (McIntosh et al. 1980; Ågmo and Paredes 1988), an effect that could be 
completely antagonized by naloxone. Although the intrinsic effects of naloxone on male sexual 
behavior are somewhat controversial (Gessa et al. 1979; McIntosh et al. 1980; Myers and Baum 
1979), in our hands doses of 5 and 10 mg/kg are behaviorally silent, whereas the 20-mg/kg dose 
appeared inhibitory. The dose-response curve of tramadol shows a steep decrease in sexual be-
havior between the 40 and 50-mg/kg doses. Although part of this inhibition is due to blockade of 
the µ-opioid receptor, antagonism of this effect by naloxone cannot completely overcome the 
tramadol-induced inhibition of sexual behavior. The remaining inhibitory effects might be due to 
stronger SSRI effects at the 50-mg/kg dose or to other effects exerted by tramadol at higher dos-
es, e.g. norepinephrine-reuptake inhibition or other m chanisms (see Minami et al. 2015).    
It is postulated that the potential inhibitory action of SSRIs on sexual behavior may be mediated 















an SSRI strongly (and dose-dependently) inhibits sexual behavior, even at doses of the SSRI (10 
mg/kg IP paroxetine) that acutely do not exert intrinsic inhibitory activity. WAY100,635, a po-
tent and selective 5-HT1A receptor antagonist has no intrinsic activity in sexual behavior, but 
strongly decreases sexual activities when it (at doses of 0.1, 0.3 and 1 mg/kg) is combined with 
10 mg/kg paroxetine. When tramadol, at a selected dose (25 mg/kg IP) that on itself does not af-
fect sexual behavior, is combined with a selected (1 mg/kg IP) dose of WAY100,635, a strong 
reduction in sexual behavior is found, supporting the role of the 5-HT reuptake inhibiting mecha-
nism of tramadol in its inhibitory effect in sexual behavior. Drug-discrimination studies in rats 
(Filip et al. 2004) where a 20-mg/kg dose (IP) of tramadol was trained as discriminative stimulus 
(DS) versus saline, supported a role for the opiate mechanism in tramadol, because morphine (2 
mg/kg) fully substituted for the tramadol cue, whereas the DS could be completely antagonized 
by naloxone at rather low dosages (ED50 around 0.2 mg/kg).  Remarkably, neither noradrenaline 
(NRI), serotonin (SSRI) nor mixed NE/5-HT reuptake blockers (SNRI) were able to substitute for 
the tramadol DS, whereas NRIs, but not SSRIs were able to shift the dose-response curve to the 
left. It is well known that SSRIs are notoriously difficult to train as a DS in rats (Olivier 2015) 
whereas NRIs create trainable cues (Caldarone et al. 2010; Dekeyne et al. 2001).  Tramadol, via 
its (-)-enantiomer and (-)-metabolite, has norepinehrine reuptake inhibiting effects that may con-
tribute to its sexual inhibitory effects at higher doses.  In general NRIs (e.g. reboxetine, 
milnacepram) are not known as antidepressants with strong sexual side effects (Graf et al. 2014; 
Segraves and Balon 2014); enhancement of NE-neurotransmission could even functionally an-
tagonize the inhibitory actions of SSRIs on sexual behavior (Bijlsma et al. 2014). Based on our 
data, we postulate that the SSRI component in tramadol is primarily responsible for the inhibitory 
















From these findings, it is predicted that tramadol, at non-sexual behavior inhibiting doses after 
acute administration, will exert inhibitory effects after (sub) chronic dosing, in analogy to those 
properties of SSRIs (Chan et al. 2008). Whether the µ-opioid receptor agonistic properties of 
tramadol contribute significantly to these effects is as yet unclear and would need more studies. 
Testing tramadol on sexual behavior in SERT-knockout rats will determine whether the opioid 
agonistic activity in tramadol exerts sexual inhibitory effects in the absence of the SERT-
inhibiting effects of tramadol. These experiments will be performed in the near future. 
The SSRI component of tramadol alone seems sufficient (compared to paroxetine) to explain 
tramadol’s inhibitory effects on sexual behavior in humans with premature ejaculation (Eassa and 
El-Shazly 2013; Yang et al. 2013). Although our data suggests that the µ-opioid component in 
tramadol might contribute to this effect, the question remains what this means in clinical practice. 
The human data suggest no clear ’on demand’ treatment effects of tramadol, although studies 
performed up to date have not realistically looked into that aspect. 
 
5. Conclusions  
The results indicate that the sexual inhibitory effects of tramadol after acute administration and 
relatively high doses are mainly mediated via the SSRI component of tramadol, although a small 
effect of the µ-opioid agonistic mechanism might contribute to this inhibitory effect. 
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Figure 1: Sexual behavior of male rats (N=12/ group) treated with vehicle, 10, 20 or 40 mg/kg 
tramadol. Data are given as mean + SEM. The number of jaculations per 30 min (A), number of 
Mounts (B), Intromissions (C), Post-ejaculatory Interval (D) and Copulatory Efficiency (E) of the 
first Ejaculation Series are given. Detailed statisical analyses (ANOVA) are shown in Suppl. 
Table 1.  
 
Figure 2: Sexual behavior of male rats (N=8/group) treated with saline + saline, tramadol 50 
mg/kg + saline, or tramadol 50 mg/kg + naloxone 10 mg/kg. Data are given as mean + SEM. The 
number of ejaculations per 30 min (A), number of Mounts (B), Intromissions (C), Post-
ejaculatory Interval (D), Copulatory Efficiency (E), Latency to first Mount (F), Latency to first 
Intromission (G) and Latency to first Ejaculation (H) of the first Ejaculation Series are given. 
Detailed statistical analyses (ANOVA) are shown in Suppl. Table 2. *: significant difference 
(P<0.05) compared to Vehicle + saline group. §: significant difference between tramadol + saline 
group and tramadol + naloxone group (P<0.05). 
 
Figure 3: Sexual behavior of male rats (N=8/group) treated with saline + saline, naloxone 20 
mg/kg + saline, or tramadol 50 mg/kg + naloxone 20 mg/kg. Data are given as mean + SEM. The 
number of ejaculations per 30 min (A), number of Mounts (B), Intromissions (C), Post-
ejaculatory Interval (D), Copulatory Efficiency (E), Latency to first Mount (F), Latency to first 
Intromission (G) and Latency to first Ejaculation (H) of the first Ejaculation Series are given. 
Detailed statistical analyses (ANOVA) are shown in Suppl. Table 4. *: significant difference 
(P<0.05) compared to saline + saline group. §: significa t difference between naloxone + saline 
group and tramadol + naloxone group (P<0.05). 
 
 Figure 4:  Sexual behavior of male rats (N=8/group) treated with saline + saline, WAY100,635 
(1 mg/kg) mg/kg + saline, or tramadol 25 mg/kg + WAY100,635 1 mg/kg. Data are given as 
mean + SEM. The number of ejaculations per 30 min (A), number of Mounts (B), Intromissions 
(C), Post-ejaculatory Interval (D), Copulatory Efficiency (E), Latency to first Mount (F), Latency 
to first Intromission (G) and Latency to first Ejaculation (H) of the first Ejaculation Series are 
given. Detailed statistical analyses (ANOVA) are shown in Suppl. Table 5. *: significant differ-
ence (P<0.05) compared to saline + saline group. §: significant difference between WAY100,635  
+ saline group and tramadol + WAY100,635 group (P<0.05). 
 
Figure 5: Sexual behavior of male rats (N=8/group) treated with saline + saline, WAY100,635 
(0.1 mg/kg) + saline, WAY100,635 (0.3 mg/kg) + saline, saline +paroxetine (10 mg/kg), 
WAY100635 (0.1 mg/kg) + paroxetine (10 mg/kg) and WAY100,635 (0.3 mg/kg) + paroxetine 
(10 mg/kg). Data are given as mean + SEM. The number of jaculations per 30 min (A), number 
of Mounts (B), Intromissions (C), Post-ejaculatory Interval (D), Copulatory Efficiency (E), La-
tency to first Mount (F), Latency to first Intromiss on (G) and Latency to first Ejaculation (H) of 
the first Ejaculation Series are given. Detailed stati ical analyses (ANOVA) are shown in Suppl. 
Table 7. a: significant difference (P<0.05) compared to saline + saline group. b: significant dif-
ference compared to WAY100,365 (0.1 mg/kg) + saline group (P<0.05). c: significant difference 
compared to WAY100,635 (0.3 mg/kg) + saline group. d: significant difference compared to sa-


















Suppl. table 1:  Effects of Tramadol on Sexual Behavior of male Wistar rats. N=12/group  
Dose of tramadol, 
mg/kg 
0 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg ANOVA significance 
Parameters 
measured 
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM  
# E 2.4±0.2 2.08±0.3 1.75±0.3 1.42±0.5 F(3,44)=2.222; P=0.178 
Latency 1st M (s) 26.1±13.3 7.46±2.1 55.4±145.2 43.2±10.6 F(3,44)=0.848; P=0.475 
Latency 1st I (s) 46.5±25.6 62.0±19.4 76.9±116.5 231.3±124.4 F(3,44)=1.633; P=0.189 
# M 1st series 20.3±3.8 16.8±3.6 23.6±6.1 15.1±3.4 F(3,44)=0.739; P=0.534 
# I 1st series 7.4±1.0 7.1±0.9 7.5±0.9 5.3±0.8 F(3,44)=1.269; P=0. 297 
Latency 1st E (s) 541.9±126.9 642.7±166.5 873.1±170.7 1020.4±210.3 F(3,44)=1.610; P=0.201 
PEL1 428.5±125.7 557.4±167.9 569.4±166.3 1064.8±221.7 F(3,44)=2.606; P=0.064 
IR1 32.7±4.7 33.9±4.2 36.4±6.6 31.0±3.8 F(3,44)=0.204; P=0.893 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-























0 mg/kg + 0 
mg/kg 
A 
50 mg/kg + 
Saline 
B 







Mean ± SEM Mean ± SEM Mean ± SEM   
# E 2.4±0.4 0.0±0.0* 0.8±0.4*  F(2,21)=12.781; P<0.001 
Latency 1st M (s) 5.2±1.1 1593.7±203.1* 574.4±272.9 (bc)  F(2,21)=16.789; P<0.001 
Latency 1st I (s) 32.7±16.4 1760.2±39.8* 948.4±273.3*  (bc)  F(2,21)=29.284; P<0.001 
# M 1st series 21.4±7.8 0.5±0.4* 4.5±1.9  F(2,21)=5.767; P=0.010 
# I 1st series 7.0±1.7 0.3±0.3* 1.9±1.0*  F(2,21)=9.637; P=0.001 
Latency 1st E (s) 598.9±217.8 1800±0.0* 1364.4±256.8*  F(2,21)=9.782; P=0.001 
PEL1 502.9±186.1 1800±0.0* 1447.5±231.1*  F(2,21)=15.327; P<0.001 
IR1 33.5±7.0 20.0±20.0 (n=2) 30.8±8.8 (n=6)  F(2,13)=0.320; P=0.732 
 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-
tromission Ratio = [# intromissions / (# intromissions + # mounts)]*100 
* = Significantly (P<0.05) different from 0 mg/kg. 
 (bc) = significantly (P<0.05) different between 50 mg/kg + saline (B) and 50 mg/kg + 10mg/kg 


















Suppl. table 3:  Effects of Naloxone and Paroxetine on Sexual Behavior of male Wistar rats. 
N=8 animals/group 
 
Dose of drug, 
mg/kg IP 
0 mg/kg (sa-
line + saline) 
5 mg/kg  
Naloxone +  
Saline 
10 mg/kg 






Parameters  Mean± SEM Mean± SEM  Mean± SEM Mean± SEM  
# E 1.0±0.5 1.3±0.6 2.3±0.7 1.0±0.5 F(3,28)=1.150; P=0. 346 
Latency 1st M (s) 21.5±7.5 12.5±2.8 20.5±8.8 46.9±20.7 F(3,28)=1.557; P=0.222 
Latency 1st I (s) 21.5±5.4 27.9±11.9 44.9±26.4 56.2±17.0 F(3,28)=0.835; P=0.486 
# M 1st series 8.9±2.2 14.9±5.0 14.1±4.1 12.4±3.6 F(3,28)=0.473; P=0.703 
# I 1st series 9.6±2.7 7.9±0.6 8.5±1.8 8.3±4.4 F(3,28)=0.085; P=0. 968 
Latency 1st E (s) 319.9±90.2 531.9±144.1 704.4±261.7 725.1±249.0 F(3,28)=0.888; P=0.460 
PEL1 283.2±23.1 120.9±216.1 251.5±53.5 60.4±290.4 F(3,24 )=1.820; P=0.170 
IR1 51.2±4.6 41.4±5.3 43.2±5.7 33.8±8.9 F(3,27)=0.788; P=0.511 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-
















Suppl. table 4:  Effects of Naloxone and Tramadol on Sexual Behavior of male Wistar rats. 
N=8 animals per group 
 




















Mean± SEM Mean± SEM Mean± SEM  
# E 2.6±0.3 0.6±0.3* 0.4±0.2* F(2,21)=26.545; P <0.001 
Latency 1st M (s) 8.4±5.0 114.3±60.7 743.5±310.1* F(2,21)=4.744; P=0.020 
Latency 1st I (s) 11.5±2.2 249.6±146.3 1213.8±295.8* ; (bc) F(2,21)=11.167; P<0.001 
# M 1st series 11.9±4.4 29.3±9.6 4.5±1.7 F(2,21)=4.208; P=0.029 
# I 1st series 5.6±1.0 5.8±1.2 2.9±1.6 (bc) F(2,21)=1.618; P=0.222 
Latency 1st E (s) 288.0±62.4 1262.5±228.2* 1522.6±171.8* F(2,21)=14.869;P<0.001 
PEL1 318.5±18.1 1099.8±264.9* 1456.1±225.2* F(2,21)8.379; P=0.002 
IR1 41.1±7.3 19.2±4.1  26.5±11.3 F(2,18)=2.798; P=0.092 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-
tromission Ratio = [# intromissions / (# intromissions + # mounts)]*100 
* = Significantly (P<0.05) different from 0 mg/kg. 
 (bc) = significantly (P<0.05) different between 20 mg/kg Naloxone + saline (B) and 20 mg/kg 


















Suppl. table 5:  Effects of WAY100635 (5-HT1A receptor antagonist) and Tramadol on Sex-
ual Behavior of male Wistar rats. N=8/group 
 
 


















Mean±SEM Mean±SEM Mean±SEM  
# E 3.1±0.4 2.4±0.3 0.3 ±0.2* (bc) F(2,21)=22.582; P<0.001 
Latency 1st M (s) 14.9±7.0 18.0±11.5 895.9 ±303.5* (bc) F(2,17)=9.967; P=0.001 
Latency 1st I (s) 50.9±26.0 68.7±42.1 926.7 ±328.7* (bc) F(2,17)=8.020; P=0.004 
# M 1st series 11.6±2.4 12.6±4.6 10.0±5.8 F(2,17)=0.085; P=0.919 
# I 1st series 6.1±0.8 5.6±0.7 3.2±1.5 F(2,17)-2.323; P=0.128 
Latency 1st E (s) 407.9±110.2 356.7±104.8 1482.0±201.3* (bc) F(2,17)-19.774; P<0.001 
PEL1 305.5±20.5 291.3±17.0 1558.2 ±241.8* (bc) F(2,17)=31.761; P<0.001 
IR1 37.0±5.2 40.8±7.8 31.4±10.5 (n=4) F(2,15)=0.338; P=0.719 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-
tromission Ratio = [# intromissions / (# intromissions + # mounts)]*100 
* = Significantly (P<0.05) different from 0 mg/kg. 
 
(bc) = significantly (P<0.05) different between 1 mg/kg WAY100635 + saline (B) and 1 mg/kg 















Suppl. table 6:  Effects of Tramadol on Sexual Behavior of male Wistar rats. N=8/group 
 












Mean±SEM Mean±SEM Mean±SEM  
# E 2.8±0.5 2.3±0.5 1.5±0.5 F(2,21)=1.797; P=0.190 
Latency 1st M (s) 4.7±1.5 12.2±3.5 344.0±197.7 F(2,21)=2.880P=0.078 
Latency 1st I (s) 29.8±12.2 50.8±16.8 348.6±211.2 F(2,21)=2.110; P=0.145 
# M 1st series 23.0±6.8 20.9±7.8 17.4±5.8 F(2,21)0.171; P=0.844 
# I 1st series 7.5±1.0 7.0±1.5 5.6±1.6 F(2,21)=0.492; P=0.618 
Latency 1st E (s) 566.7±200.2 673.1±215.4 1062.9±252.2 F(2,21)=1.364; P=0.277 
PEL1 473.0±189.9 508.4±185.5 1081.0±272.1 F(2,21)=2.418; P=0.113 
IR1 29.8±5.1 33.7±5.3 25.8±4.9 F(2,21)=0.569; P=0.575 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number; IR= In-















Suppl. table 7:  Effects of WAY100635 (5HT1A receptor antagonist) and Paroxetine on Sexual Behavior of male Wistar rats. 
N=8/group  
 



































Mean± SEM Mean± SEM Mean± SEM Mean± SEM Mean± SEM Mean± SEM  
# E 2.4±0.2 1.5±0.5 2.5±0.3 1.5±0.4 0.0±0.0*; b;d 0.0±0.0*;c;d F(5,42)=13.619; P<0.001 
Latency 1st M (s) 19.3±11.1 88.9±74.3 8.1±2.2 54.4±33.8 923.9±286.1*; b;d 1527.2±;222.7* c;d F(5,42)=17.810; P<0.001 
Latency 1st I (s) 25.5±14.4 350.0±213.8 21.0±10.1 451.2±221.3 1415.2±190.3*;b;d 1800.0±0.0*;c;d F(5,42)=25.780; P<0.001 
# M 1st series 15.6±3.9 19.1±7.3 12.4±2.0 13.8±3.6 6.6±2.8 1.1±1.0 F(5,42)=2.696; P=0.034 
# I 1st series 10.5±4.7 4.3±0.8 10.0±2.2 4.8±2.1 0.8±0.3 0.0±0.0* ; F(5,42) =5.700; P=0.007 
Latency 1st E (s) 352.9±57.6 1008.3±241.6 501.9±127.4 986.3±44.7 1800.0±0.0*;b;d 1800.0±0.0*;c;d F(5,42)=16.639; P<0.001 
PEL1 344.3±16.2 693.3±242.9 347.7±20.7 895.9±265.3 1800 .0±0.0*;b;d 1800.0±0.0*;c;d F(5,42)=20.648; P<0.001 
IR1 40.0±6.8 35.5±11.1 44.6±4.9 31.0±6.3 n=4; 15.7±6.1 n =0 F(5,42)=1.462; P=0.238 
 
M=Mount; I= Intromission; E=Ejaculation; PEL=post-ejaculatory interval; # =number;  
IR= Intromission Ratio = [# intromissions / (# intromissions + # mounts)]*100 
* = Significantly (P<0.05) different from 0 mg/kg. 
 
b = significantly (P<0.05) different from 0.1 mg/kg WAY100635 + saline (B); c = significantly (P<0.05) different from 0.3 mg/kg 
















































































• Paroxetine resembled the inhibitory effects of tramadol on sexual behavior 
• 5-HT1A receptor antagonist combined with tramadol strongly decreased sexual behavior 
• µ-opioid receptor antagonist only partially antagonized the effects of tramadol 
• Tramadol’s sexual inhibitory effects are primarily caused by its SSRI properties 
 
